Competition

Competitive Position — Topicus vs the VMS Roll-Up Cohort

Figures converted from EUR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Topicus.com's moat is real but borrowed. The "decentralised serial acquirer" playbook was built by Constellation Software; Topicus runs the European edition of it with the same hurdle-rate discipline, similar margins (~28% EBITDA), and a near-identical revenue mix. The one peer that matters is therefore not a competitor at all — it is the parent, CSU — because CSU's continued willingness to leave European mid-market VMS deals to Topicus is what protects the runway. The real bidders for Topicus' deals are European private-equity roll-ups (Visma, Cegid, TeamSystem, Asseco) that the public peer set does not contain. Among public peers, Topicus' deal velocity beats Vitec and Enghouse and trails only CSU/Lumine, and its 4% organic growth sits between LMN/CSU (3–6%) and ENGH/VIT-B (~0% same-store). The picture is of a moat that is genuine on the customer side (mission-critical software, 6% organic maintenance growth, eight years of 27–32% EBITDA margins) but structurally exposed on the deal-supply side to European PE bid intensity and to any change in CSU family lane allocation.

All TOI-specific figures in this file are converted to US dollars at the relevant period-end EUR/USD rate; peer figures are already in USD millions.

Competitive Bottom Line

Topicus has a legitimate advantage, not an overstated one — but the advantage is more about access (Mark-Leonard-trained operators, European seller trust, decentralised hold-forever promise) than about product. On any like-for-like VMS metric (organic growth, FCF conversion, ROIC ex-amortisation, customer renewal rates), Topicus is roughly indistinguishable from CSU and clearly stronger than Enghouse or Vitec on deal velocity. The competitor type that matters most for the next five years is European private-equity-backed VMS roll-ups — Visma, Cegid, TeamSystem, Asseco, Volaris-Europe — that compete for the same family-owned targets. None are in the public peer set because none are listed; that absence is itself the story. Among public peers, Lumine is the "what if Topicus had a faster engine" comparison; Enghouse is the cautionary "what if the engine stalls" case.

The Right Peer Set

Five public peers were selected to triangulate three distinct questions an investor must answer about Topicus.

Three takeaways. (1) TOI sits on top of CSU in both axes — same margin, same multiple, one-seventh the scale. The market is pricing TOI as "CSU at year fifteen" not as a structurally different bet. (2) Lumine commands a premium for being earlier in its compounding cycle (15% revenue growth FY2025 vs TOI's 20% acquisition-fuelled / 4% organic). (3) Enghouse is the warning — same model, no deal flow, multiple compressed to ~4× EBITDA. That maps the downside case if the European pipeline stops working.

Where The Company Wins

Topicus has four specific competitive edges, each with concrete supporting evidence.

The maintenance-line picture is the cleanest tell. Topicus and CSU compound the recurring base at ~6%; Lumine ~4%; Vitec and Enghouse are at or near zero on same-store recurring. The latter two are not failing companies, but they are the case studies for a moat that has stopped compounding organically. TOI's gap to them is the empirical proof that the Constellation-family deal sourcing and decentralised price-discipline are working.

* TOI bar adds $450M into Asseco Poland to the $330M of VMS acquisitions. Topicus and CSU are the only two peers running acquisitions above 50% of trailing FCF in FY2025; Lumine collapsed from ~125% in FY2024 to 6% in FY2025 (it ingested Lumine's first three-year acquisition surge and is now digesting); Enghouse and Vitec are running at ENGH-pattern <70% of FCF — accumulating cash with no place to put it. The TOI bar above 100% says management is leaning into the cycle, not just maintaining it. That is the difference between TOI compounding at ~20% IRR and Enghouse rerating to a low single-digit EBITDA multiple.

Where Competitors Are Better

Every peer beats Topicus on at least one dimension.

Reading the row pattern: TOI is the second-best player on six of the eight dimensions — never the worst, never the best except for European VMS focus and FY25 capital deployment. That is consistent with the share-price level relative to CSU, but it explains why the multiple does not expand: there is no axis on which TOI clearly beats the parent.

Threat Map

Threats below are limited to those with specific evidence — generic "competition is intense" claims are excluded.

Moat Watchpoints

Five measurable signals tell the story. Track these quarterly; do not bother with EPS prints.

The most diagnostic of the five is #2 (capital deployed vs FCFA2S). Looking sideways across the public peer set in FY2025: TOI 166% (leaning in), CSU 50% (slowing), ADDT-B 63%, VIT-B 68%, ENGH 32% (stalled), LMN 6% (post-binge digestion). Topicus is currently the only public peer where capital deployed exceeded operating free cash flow in FY2025, including via the Asseco stake. A reversion to 50–80% in FY2026 would be normal cycle behaviour. A drop to ENGH levels (under 35%) for two consecutive years would indicate the European deal funnel has narrowed materially. That single number, more than any earnings or margin print, is the most direct read on whether Topicus holds a CSU-like multiple or compresses toward Enghouse.